• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

多巴胺激动剂/拮抗剂[3H]特古瑞得(反式二氢麦角隐亭)在大鼠纹状体中的结合特性

Binding characteristics of the dopamine agonist/antagonist [3H]terguride (transdihydrolisuride) in the rat striatum.

作者信息

Valchár M, Vrsecká M, Krejcí I, Dlabac A

出版信息

Eur J Pharmacol. 1987 Apr 7;136(1):97-101. doi: 10.1016/0014-2999(87)90784-9.

DOI:10.1016/0014-2999(87)90784-9
PMID:3297739
Abstract

The binding properties of [3H]terguride were studied in various regions of the rat brain. The highest density of [3H]terguride binding sites was found in the striatum and tuberculum olfactorium. In the striatum, the binding was saturable, stereoselective and of a high affinity. There was a good correlation between the inhibition of [3H]terguride and [3H]spiperone bindings by various dopaminergic agents. Drugs with affinity to another type of receptors did not displace [3H]terguride binding in the striatum; only SCH 23390 was effective. The experiments indicate a certain affinity of the ligand to D-1 receptors. Nevertheless, [3H]terguride appears to have an affinity to D-2 receptors in the striatum and, thanks to its dopamine agonistic/antagonistic profile, would be useful in the further study of dopamine receptors.

摘要

研究了[3H]泰必利在大鼠脑不同区域的结合特性。在纹状体和嗅结节中发现[3H]泰必利结合位点密度最高。在纹状体中,结合具有饱和性、立体选择性且亲和力高。各种多巴胺能药物对[3H]泰必利和[3H]螺哌隆结合的抑制之间存在良好的相关性。对另一类受体有亲和力的药物不会取代纹状体中[3H]泰必利的结合;只有SCH 23390有效。实验表明该配体对D-1受体有一定亲和力。然而,[3H]泰必利似乎对纹状体中的D-2受体也有亲和力,并且由于其多巴胺激动/拮抗特性,将有助于多巴胺受体的进一步研究。

相似文献

1
Binding characteristics of the dopamine agonist/antagonist [3H]terguride (transdihydrolisuride) in the rat striatum.多巴胺激动剂/拮抗剂[3H]特古瑞得(反式二氢麦角隐亭)在大鼠纹状体中的结合特性
Eur J Pharmacol. 1987 Apr 7;136(1):97-101. doi: 10.1016/0014-2999(87)90784-9.
2
Comparison of (3H)-terguride and (3H)-spiperone binding to dopamine receptors in the rat striatum.
Act Nerv Super (Praha). 1989 Apr;31(1):77-9.
3
Selective blockade of dopamine D-1 receptor by SCH 23390 affects dopamine agonist binding to 3H-spiperone labeled D-2 receptors in rat striatum.SCH 23390对多巴胺D-1受体的选择性阻断作用会影响多巴胺激动剂与大鼠纹状体中用3H-螺哌啶标记的D-2受体的结合。
Jpn J Pharmacol. 1989 Jul;50(3):333-45. doi: 10.1254/jjp.50.333.
4
Effects of GTP and sodium on rat striatal dopamine receptors labeled with lisuride.鸟苷三磷酸(GTP)和钠对用利苏瑞ide标记的大鼠纹状体多巴胺受体的影响。
Brain Res. 1982 Sep 23;248(1):185-7. doi: 10.1016/0006-8993(82)91162-3.
5
Guanine nucleotides reveal differential actions of ergot derivatives at D-2 receptors labelled by [3H]spiperone in striatal homogenates.鸟嘌呤核苷酸揭示了麦角衍生物对纹状体匀浆中由[³H]螺哌隆标记的D-2受体的不同作用。
Brain Res. 1983 Nov 14;278(1-2):155-63. doi: 10.1016/0006-8993(83)90234-2.
6
Direct binding of 3H-lisuride to adrenergic and serotonergic receptors.3H-利苏立得与肾上腺素能和血清素能受体的直接结合。
Life Sci. 1981 Aug 31;29(9):909-16. doi: 10.1016/0024-3205(81)90392-1.
7
Effects of the partial dopamine receptor agonists SDZ 208-911, SDZ 208-912 and terguride on central monoamine receptors. A behavioral, biochemical and electrophysiological study.部分多巴胺受体激动剂SDZ 208 - 911、SDZ 208 - 912和替古瑞定对中枢单胺受体的影响。一项行为、生化和电生理研究。
Naunyn Schmiedebergs Arch Pharmacol. 1991 Sep;344(3):263-74. doi: 10.1007/BF00182999.
8
The binding characteristics of 3H-terguride in various brain areas.3H-泰必利在不同脑区的结合特性。
Act Nerv Super (Praha). 1989 Dec;31(4):274-5.
9
6-hydroxydopamine treatments enhance behavioral responses to intracerebral microinjection of D1- and D2-dopamine agonists into nucleus accumbens and striatum without changing dopamine antagonist binding.6-羟基多巴胺处理增强了对向伏隔核和纹状体内脑微量注射D1和D2多巴胺激动剂的行为反应,而不改变多巴胺拮抗剂结合。
J Pharmacol Exp Ther. 1987 Jan;240(1):167-76.
10
Distinctions between ligand-binding sites for [3H]dopamine and D2 dopaminergic receptors characterized with [3H]spiroperidol.用[3H]螺哌啶醇表征的[3H]多巴胺配体结合位点与D2多巴胺能受体之间的区别。
Mol Pharmacol. 1984 Nov;26(3):439-51.